Comparison of anti-tuberculosis regimens using fixed dose combination versus single drugs

A. Messadi, S. Toujani, M. Osman, Ben Salah, N. Mehiri, H. Zakhama, Y. Wahchi, J. Cherif, Z. Souissi, B. Louzir, J. Daghfous, M. Beji (Tunis, Tunisia)

Source: Annual Congress 2010 - Prognosis of tuberculosis
Session: Prognosis of tuberculosis
Session type: Thematic Poster Session
Number: 3109
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Messadi, S. Toujani, M. Osman, Ben Salah, N. Mehiri, H. Zakhama, Y. Wahchi, J. Cherif, Z. Souissi, B. Louzir, J. Daghfous, M. Beji (Tunis, Tunisia). Comparison of anti-tuberculosis regimens using fixed dose combination versus single drugs. Eur Respir J 2010; 36: Suppl. 54, 3109

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019

Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit?
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011


Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation?
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018

Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen
Source: Annual Congress 2012 - Tuberculosis: clinical findings I
Year: 2012

The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017

Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012


Evaluation of antituberculous drugs administration
Source: Eur Respir J 2002; 20: Suppl. 38, 547s
Year: 2002

Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020
Year: 2020



Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease
Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Year: 2010


Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007



LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again?
Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Year: 2018


Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008


Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen
Source: Eur Respir J 2003; 22: Suppl. 45, 411s
Year: 2003

Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis
Source: ISSN=ISSN 1810-6838, ISBN=, page=69
Year: 2007

Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021


Individualized treatment regimens with second line anti-TB drugs (SLD) compared to first line anti-TB drug (FLD) only in new pulmonary TB patients, culture confirmed with full sensibility at drug sensibility test (DST)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012

The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017